{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T16:48:50Z","timestamp":1771260530667,"version":"3.50.1"},"reference-count":18,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2005,5,1]],"date-time":"2005-05-01T00:00:00Z","timestamp":1114905600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2005,5]]},"DOI":"10.1016\/j.clinthera.2005.05.010","type":"journal-article","created":{"date-parts":[[2005,6,23]],"date-time":"2005-06-23T07:21:43Z","timestamp":1119511303000},"page":"594-598","source":"Crossref","is-referenced-by-count":31,"title":["Oral absorption kinetics of levetiracetam: The effect of mixing with food or enteral nutrition formulas"],"prefix":"10.1016","volume":"27","author":[{"given":"Monica A.","family":"Fay","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Raj D.","family":"Sheth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barry E.","family":"Gidal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2005.05.010_bib1","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1528-1157.2000.tb04605.x","article-title":"Efficacy and tolerability of levetiracetam 3000 mg\/d in patients with refractory partial seizures: A multicenter, double-blind, responder-selected study evaluating monotherapy","volume":"41","author":"Ben-Menachem","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinthera.2005.05.010_bib2","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1053\/seiz.2000.0380","article-title":"A multicentre, double-blind, randomized, parallel group study to evaluate the tolerability and efficacy of two oral doses of levetiracetam, 2000 mg daily and 4000 mg daily, without titration in patients with refractory epilepsy","volume":"9","author":"Betts","year":"2000","journal-title":"Seizure"},{"key":"10.1016\/j.clinthera.2005.05.010_bib3","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1212\/WNL.55.2.236","article-title":"Levetiracetam for partial seizures: Results of a double-blind, randomized clinical trial","volume":"55","author":"Cereghino","year":"2000","journal-title":"Neurology"},{"key":"10.1016\/j.clinthera.2005.05.010_bib4","first-page":"250","article-title":"In vitro evaluation of potential drug interactions with levetiracetam, a new antiepileptic drug","volume":"27","author":"Nicolas","year":"1999","journal-title":"Drug Metab Dispos"},{"key":"10.1016\/j.clinthera.2005.05.010_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/S0920-1211(02)00250-4","article-title":"Effects of antiepileptic comedication on levetiracetam pharmacokinetics: A pooled analysis of data from randomized adjunctive therapy trials","volume":"53","author":"Perucca","year":"2003","journal-title":"Epilepsy Res"},{"issue":"Suppl 7","key":"10.1016\/j.clinthera.2005.05.010_bib6","first-page":"254","article-title":"Levetiracetam does not interact with other antiepileptic drugs","volume":"41","author":"Perucca","year":"2000","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinthera.2005.05.010_bib7","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0920-1211(01)00293-5","article-title":"Lack of effect of repeated administration of levetiracetam on the pharmacodynamic and pharmacokinetic profiles of warfarin","volume":"47","author":"Ragueneau-Majlessi","year":"2001","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.clinthera.2005.05.010_bib8","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1046\/j.1528-1157.2002.57701.x","article-title":"Levetiracetam does not alter the pharmacokinetics of an oral contraceptive in healthy women","volume":"43","author":"Ragueneau-Majlessi","year":"2002","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinthera.2005.05.010_bib9","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1046\/j.1528-1157.2001.0420s4024.x","article-title":"Pharmacokinetics of levetiracetam","volume":"42","author":"Radtke","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.clinthera.2005.05.010_bib10","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0163-7258(99)00052-2","article-title":"Pharmacokinetic profile of levetiracetam: Toward ideal characteristics","volume":"85","author":"Patsalos","year":"2000","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2005.05.010_bib11","unstructured":"Keppra [package insert]. Smyrna, Ga: UCB Pharma, Inc; 2000."},{"key":"10.1016\/j.clinthera.2005.05.010_bib12","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1345\/aph.19355","article-title":"Phenytoin and enteral feedings: Does evidence support an interaction?","volume":"34","author":"Au Yeung","year":"2000","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2005.05.010_bib13","first-page":"796","article-title":"Phenytoin-enteral feeding interaction","volume":"23","author":"Haley","year":"1989","journal-title":"DICP"},{"key":"10.1016\/j.clinthera.2005.05.010_bib14","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1097\/00007691-198606000-00007","article-title":"Review of alterations in oral phenytoin bioavailability associated with formulation, antacids, and food","volume":"8","author":"Cacek","year":"1986","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.clinthera.2005.05.010_bib15","series-title":"Antiepileptic Drugs","first-page":"565","article-title":"Phenytoin and other hydantoins: Chemistry and biotransformation","author":"Browne","year":"2002"},{"key":"10.1016\/j.clinthera.2005.05.010_bib16","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1177\/0148607190014005513","article-title":"Phenytoin interaction with enteral feedings administered through nasogastric tubes","volume":"14","author":"Fleisher","year":"1990","journal-title":"J Parenter Enteral Nutr"},{"key":"10.1016\/j.clinthera.2005.05.010_bib17","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1345\/aph.17281","article-title":"Gabapentin absorption: Effect of mixing with foods of varying macronutrient composition","volume":"32","author":"Gidal","year":"1998","journal-title":"Ann Pharmacother"},{"key":"10.1016\/j.clinthera.2005.05.010_bib18","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1177\/00912700122010005","article-title":"The influence of food on the bioavailability of a twice-daily controlled release carbamazepine formulation","volume":"41","author":"McLean","year":"2001","journal-title":"J Clin Pharmacol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929180500086X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S014929180500086X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,6,21]],"date-time":"2018-06-21T01:35:12Z","timestamp":1529544912000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S014929180500086X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,5]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2005,5]]}},"alternative-id":["S014929180500086X"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2005.05.010","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2005,5]]}}}